Description

IDEXX Acquisition Of CoVetAI Could Drive The Next Phase Of Diagnostic Growth!

IDEXX Laboratories has moved deeper into veterinary artificial intelligence with its September 16, 2026 acquisition of CoVetAI, an AI-native clinical workflow platform designed to automate documentation, organize patient information, and streamline communication across veterinary practices. Financial terms were not disclosed, but the strategic logic extends beyond simply adding an ambient scribe product. CoVetAI will be integrated into IDEXX’s broader software, diagnostics, and AI ecosystem while continuing to support non-IDEXX practice management systems and third-party integrations. The transaction follows a strong operational period for IDEXX, which reported approximately 10% second-quarter revenue growth, more than 10% organic growth in Companion Animal Group diagnostic recurring revenues, and continued expansion across inVue Dx, Cancer Dx, cloud-based practice management software, and Vello. Management had also indicated that business development opportunities in diagnostics and software remained under active review, making CoVetAI closely aligned with IDEXX’s existing strategic priorities.